Temozolomide Glioma

1. Legler, J. M., Ries, L. A., Smith, M. A. et al. (1999). Cancer surveillance series [corrected]: Brain and other central nervous system cancers: Recent trends in incidence and mortality. J Natl Cancer Inst 91, 1382-1390.

2. Guha, A., Dashner, K., Black, P. M., Wagner, J. A., Stiles C. D. (1995). Expression of pdgf and pdgf receptors in human astrocytoma operation specimens supports the existence of an autocrine loop. Int J Cancer 60, 168-173.

3. Parker, S. L., Tong, T., Bolden S., Wingo, P. A. (1996). Cancer statistics, 1996. CA Cancer J Clin 46, 5-27.

4. Black, P. M. (1991). Brain tumors. Part 1. N Engl J Med 324, 1471-1476.

5. Lesniak, M. S., and Brem, H. (2004). Targeted therapy for brain tumours. Nat Rev Drug Discov 3, 499-508.

6. Kusuhara, H., and Sugiyama, Y. (2001). Efflux transport systems for drugs at the blood-brain barrier and blood-cerebrospinal fluid barrier (part 2). Drug Discov Today 6, 206-212.

7. Rautioa, J., and Chikhale, P. J. (2004). Drug delivery systems for brain tumor therapy. Curr Pharm Des 10, 1341-1353.

8. Yuan, F., Salehi, H. A., Boucher, Y. et al. (1994). Vascular permeability and microcirculation of gliomas and mammary carcinomas transplanted in rat and mouse cranial windows. Cancer Res 54, 4564-4568.

9. Jain, R. K. (1994). Barriers to drug delivery in solid tumors. Sci Am 271, 58-65.

10. Rockwell, S. (1992). Use of hypoxia-directed drugs in the therapy of solid tumors. Semin Oncol 19, 29-40.

11. Chin, H. W., Young, A. B., Maruyama, Y. (1981). Survival response of malignant gliomas to radiotherapy with or without bcnu or methyl-ccnu chemotherapy at the university of kentucky medical center. Cancer Treat Rep 65, 45-51.

12. Kornblith, P. L., and Walker, M. (1988). Chemotherapy for malignant gliomas. J Neurosurg 68, 1-17.

13. Medical Research Council Brain Tumor Working Party (2001). Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astro-cytoma: A medical research council trial. J Clin Oncol 19, 509-518.

14. Prokai, L., Prokai-Tatrai, K., and Bodor, N. (2000). Targeting drugs to the brain by redox chemical delivery systems. Med Res Rev 20, 367-416.

15. Kurihara, A., and Pardridge, W. M. (1999). Imaging brain tumors by targeting peptide radiopharmaceuticals through the blood-brain barrier. Cancer Res 59, 6159-6163.

16. Williams, P. C., Henner, W. D., Roman-Goldstein, S. et al. (1995). Toxicity and efficacy of carboplatin and etoposide in conjunction with disruption of the blood-brain barrier in the treatment of intracranial neoplasms. Neurosurgery 37, 17-28.

17. Rapoport, S. I. (2001). Advances in osmotic opening of the blood-brain barrier to enhance cns chemotherapy. Expert Opin Investig Drugs 10, 1809-1818.

18. Kobrinsky, N. L., Packer, R. J., Boyett J. M. et al. (1999). Etoposide with or without mannitol for the treatment of recurrent or primarily unresponsive brain tumors: A children's cancer group study, ccg-9881. J Neurooncol 45, 47-54.

19. Prados, M. D., Schold, S. J. S., Fine, H. A. et al. (2003). A randomized, double-blind, placebo-controlled, phase 2 study of rmp-7 in combination with carboplatin administered intravenously for the treatment of recurrent malignant glioma. Neuro-Oncol 5, 96-103.

20. Boiardi, A., Eoli, M., Pozzi, A. et al. (1999). Locally delivered chemotherapy and repeated surgery can improve survival in glioblastoma patients. Ital J Neurol Sci 20, 43-48.

21. Morantz, R. A., Kimler, B. F., Vats, T. S., Henderson, S. D. (1983). Bleomycin and brain tumors. A review. J Neurooncol 1, 249-255.

22. Patchell, R. A., Regine, W. F., Ashton, P. et al. (2002). A phase I trial of continuously infused intratumoral bleomycin for the treatment of recurrent glioblastoma multiforme. J Neurooncol 60, 37-42.

23. Voulgaris, S., Partheni, M., Karamouzis, M. et al. (2002). Intratumoral doxorubicin in patients with malignant brain gliomas. Am J Clin Oncol 25, 60-64.

24. Walter, K. A., Tamargo, R. J., Olivi, A., Buger, P. C., Brem, H. (1995). Intratumoral chemotherapy. Neurosurgery 37, 1128-1145.

25. Huang, Y., Hayes, R. L., Wertheim, S., Arbit E., and Scheff, R. (2001). Treatment of refractory recurrent malignant glioma with adoptive cellular immunotherapy: A case report. Crit Rev Oncol Hematol 39, 17-23.

26. Boiardi, A., Silvani, A., Milanesi, I. et al. (1991). Local immunotherapy (beta-ifn) and systemic chemotherapy in primary glial tumors. Ital J Neurol Sci 12, 163-168.

27. Giussani, C., Carrabba, G., Pluderi, M. et al. (2003). Local intracerebral delivery of endogenous inhibitors by osmotic minipumps effectively suppresses glioma growth in vivo. Cancer Res 63, 2499-2505.

28. Bobo, R. H., Laske, D. W., Akbasak, A. et al. (1994). Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci U S A 91, 2076-2080.

29. Chen, M. Y., Lonser, R. R., Morrison, P. F., Governale, L. S., Oldfield, E. H. (1999). Variables affecting convection-enhanced delivery to the striatum: A systematic examination of rate of infusion, cannula size, infusate concentration, and tissue-cannula sealing time. J Neurosurg 90, 315-320.

30. Degen, J. W., Walbridge, S., Vortmeyer, A. O. Oldfield, E. H., Lonser, R. R. (2003). Safety and efficacy of convection-enhanced delivery of gemcitabine or carboplatin in a malignant glioma model in rats. J Neurosurg 99, 893-898.

31. Husain, S. R., Joshi, B. H., Puri, R. K. et al. (2001). Interleukin-13 receptor as a unique target for anti-glioblastoma therapy. Int J Cancer 92, 168-175.

32. Mardor, Y., Roth, Y., Lidar, Z. et al. (2001). Monitoring response to convection-enhanced taxol delivery in brain tumor patients using diffusion-weighted magnetic resonance imaging. Cancer Res 61, 4971-4973.

33. Lidar, Z., Mardor, Y., Jonas, T. et al. (2004). Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: A phase I/II clinical study. J Neurosurg 100, 472-479.

34. Langer, R., and Folkman, J. (1976). Polymers for the sustained release of proteins and other macromolecules. Nature 263, 797-800.

35. Langer, R. S., and Wise, D. L. (1984). Medical applications of controlled release. CRC Press, Boca Raton, Fla.

36. Lewis, D. H. (1990). Controlled release of bioactive agents from lactide/glycolide polymers. In Biodegradable polymers as drug delivery systems (M. Chasin, R. and Langer, Eds.), pp. 1-41, Marcel Dekker, New York, NY.

37. Burt, H. M., Jackson, J. K., Bains, S. K. et al. (1995). Controlled delivery of taxol from microspheres composed of a blend of ethylene-vinyl acetate copolymer and poly (d,l-lactic acid). Cancer Lett 88, 73-79.

38. Sato, H., Wang, Y. M., Adachi, I., Horikoshi, I. (1996). Pharmacokinetic study of taxol-loaded poly(lactic-co-glycolic acid) microspheres containing isopropyl myristate after targeted delivery to the lung in mice. Biol Pharm Bull 19, 1596-1601.

39. Peyman, G. A., Conway, M., Khoobehi, B. Soike, K. (1992). Clearance of microsphere-entrapped 5-fluorouracil and cyto-sine arabinoside from the vitreous of primates. Int Ophthalmol 16, 109-113.

40. Torres, A. I., Boisdron-Celle, M., and Benoit, J. P. (1996). Formulation of bcnu-loaded microspheres: Influence of drug stability and solubility on the design of the microencapsulation procedure. J Microencapsul 13, 41-51.

41. Williams, R. C., Paquette, D. W., Offenbacher, S. et al. (2001). Treatment of periodontitis by local administration of mino-cycline microspheres: A controlled trial. J Periodontol 72, 1535-1544.

42. Lamprecht, A., Ubrich, N., Yamamoto, H. et al. (2001). Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease. J Pharmacol Exp Ther 299, 775-781.

43. Lee, M., Browneller, R., Wu, Z. et al. (1997). Therapeutic effects of leuprorelin microspheres in prostate cancer. Adv Drug Deliv Rev 28, 121-138.

44. Brem, H., and Langer, R. (1996). Polymer-based drug delivery to the brain. Sci Med July/August, 52-61.

45. Leong, K. W., Brott, B. C., and Langer, R. (1985). Bioerodible polyanhydrides as drug-carrier matrices. I: Characterization, degradation, and release characteristics. J Biomed Mater Res 19, 941-955.

46. Chasin, M., Domb, A., and Ron, E. (1990). Polyanhydrides as drug delivery systems. In Biodegradable polymers as drug delivery systems (M. Chasin, and R. Langer Eds.), pp. 43-70. Marcel Dekker, New York, NY.

47. Mathiowitz, E., and Langer, R. (1987). Polyanhydride micro-spheres as drug carriers. I. Hot-melt microencapsulation. J Control Rel 5, 13-22.

48. Mathiowitz, E., Saltzman, M., and Domb, A. (1988). Polyanhydride microspheres as drug carriers. Ii. Microencapsulation by solvent removal. J Appl Polym Sci 35, 755-774.

49. Bindschaedler, C., Leong, K., Mathiowitz, E. Langer, R. (1988). Polyanhydride microsphere formulation by solvent extraction. J Pharm Sci 77, 696-698.

50. Howard, M. A., III, Gross, A., Grady, M. S. et al. (1989). Intracerebral drug delivery in rats with lesion-induced memory deficits. J Neurosurg 71, 105-112.

51. Mathiowitz, E., Kline, D., and Langer, R. (1990). Morphology of polyanhydride microsphere delivery systems. Scanning Microsc 4, 329-340.

52. Langer, R., Brem, H., and Tapper, D. (1981). Biocompatibility of polymeric delivery systems for macromolecules. J Biomed Mater Res 15, 267-277.

53. Brem, H., Kader, A., Epstein, J. I. et al. (1989). Biocompatibility of a biodegradable, controlled-release polymer in the rabbit brain. Sel Cancer Ther 5, 55-65.

54. Tamargo, R. J., Epstein, J. I., Reinhard, C. S. Chasin, M., Brem, H. (1989). Brain biocompatibility of a biodegradable, controlled-release polymer in rats. J Biomed Mater Res 23, 253-266.

55. Shieh, L., Tamada, J., Chen, I. et al. (1994). Erosion of a new family of biodegradable polyanhydrides. J Biomed Mater Res 28, 1465-1475.

56. Golumbek, P. T., Azhari, R., Jaffee, E. M. et al. (1993). Controlled release, biodegradable cytokine depots: A new approach in cancer vaccine design. Cancer Res 53, 5841-5844.

57. Gabizon, A. A. (1994). Liposomal anthracyclines. Hematol Oncol Clin North Am 8, 431-450.

58. Loo, T. L., Dion, R. L., Dixon, R. L., Rall, D. P. (1966). The antitumor agent, 1,3-bis(2-chloroethyl)-1-nitrosourea. J Pharm Sci 55, 492-497.

59. Grossman, S. A., Reinhard, C., Colvin, O. M. et al. (1992). The intracerebral distribution of bcnu delivered by surgically implanted biodegradable polymers. J Neurosurg 76, 640-647.

60. Fung, L. K., Ewend, M. G., Sills, A. et al. (1998). Pharmaco-kinetics of interstitial delivery of carmustine, 4-hydroperox-ycyclophosphamide, and paclitaxel from a biodegradable polymer implant in the monkey brain. Cancer Res 58, 672-684.

61. Tamargo, R. J., Myseros, J. S., Epstein, J. I. et al. (1993). Interstitial chemotherapy of the 9l gliosarcoma: Controlled release polymers for drug delivery in the brain. Cancer Res 53, 329-333.

62. Brem, H., Tamargo, R. J., Olivi, A. et al. (1994). Biodegradable polymers for controlled delivery of chemotherapy with and without radiation therapy in the monkey brain. J Neurosurg 80, 283-290.

63. Brem, H., Mahaley, M. S., Jr, Vick, N. A. et al. (1991). Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. J Neurosurg 74, 441-446.

64. Brem, H., Piantadosi, S., Burger, P. C. et al. (1995). Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The polymer-brain tumour treatment group. Lancet 345, 1008-1012.

65. Valtonen, S., Timonen, U., Toivanen, P. et al. (1997). Interstitial chemotherapy with carmustine-loaded polymers for highgrade gliomas: A randomized double-blind study. Neurosurgery 41, 44-48.

66. Westphal, M., Hilt, D. C., Bortey, E. et al. (2003). A phase 3 trial of local chemotherapy with biodegradable carmustine (bcnu) wafers (gliadel wafers) in patients with primary malignant glioma. Neuro-Oncol 5, 79-88

67. Sipos, E. P., Tyler, B., Piantadosi, S. Burger, P. C., Brem, H. (1997). Optimizing interstitial delivery of bcnu from controlled release polymers for the treatment of brain tumors. Cancer Chemother Pharmacol 39, 383-389.

68. Olivi, A., Grossman, S. A., Tatter, S. et al. (2003). Dose escalation of carmustine in surgically implanted polymers in patients with recurrent malignant glioma: A new approaches to brain tumour therapy CNS consortium trial. J Clin Oncol 21, 1845-1849.

69. Silber, J. R., Bobola, M. S., Ghatan, S. et al. (1998). O6-methylguanine-DNA methyltransferase activity in adult gliomas: Relation to patient and tumour characteristics. Cancer Res 58, 1068-1073.

70. Friedman, H. S., Keir, S., Pegg, A. E. et al. (2002). O6-benzylguanine-mediated enhancement of chemotherapy. Mol Cancer Ther 1, 943-948.

71. Rhines, L. D., Sampath, P., Dolan, M. E. et al. (2000). O6-benzylguanine potentiates the antitumor effect of locally delivered carmustine against an intracranial rat glioma. Cancer Res 60, 6307-6310.

72. Rosenblum, M., Weingart, J., Dolan, M. E. et al. (2002). Phase I study of gliadel combined with a continuous intravenous infusion of o6-benzylguanine in patients with recurrent malignant glioma. Proc American Soc Clin Oncologists 21.

73. Lee, J. H., Chai, Y. G., and Hersh, L. B. (2000). Expression patterns of mouse repressor element-1 silencing transcription factor 4 (rest4) and its possible function in neuroblastoma. J Mol Neurosci 15, 205-214.

74. Ewend, M. G., Brem, S., Gilber, M., Goodkin, R. and Penar, P. (2001) Treating single brian metastasis with resection, placement of bcnu-polymer wafers, and radiation therapy. Am Assoc Neurol Surgeons. Abstract in CD.

75. Cahan, M. A., Walter, K. A., Colvin, O. M. et al. (1994). Cytoto-xicity of taxol in vitro against human and rat malignant brain tumors. Cancer Chemother Pharmacol 33, 441-444.

76. Forsyth, P., Cairncross, G., Stewart, D. et al. (1996). Phase II trial of docetaxel in patients with recurrent malignant glioma: A study of the national cancer institute of canada clinical trials group. Invest New Drugs 14, 203-206.

77. Freilich, R. J., Seidman, A. D., DeAngelis, L. M. (1995). Central nervous system progression of metastatic breast cancer in patients treated with paclitaxel. Cancer 76, 232-236.

78. Glantz, M. J., Chamberlain, M. C., Chang, S. M., Prados, M. D., Cole, B. F. (1999). The role of paclitaxel in the treatment of primary and metastatic brain tumors. Semin Radiat Oncol 9, 27-33.

79. Menei, P., Benoit, J. P., Boisdron-Celle, M., et al. (1994). Drug targeting into the central nervous system by stereotactic implantation of biodegradable microspheres. Neurosurgery 34, 1058-1064.

80. Li, K. W., Dang, W., Tyler, B. M. et al. (2003). Polilactofate microspheres for paclitaxel delivery to central nervous system malignancies. Clin Cancer Res 9, 3441-3447.

81. Goodman, L. S., Hardman, J. G., Limbird, L. E., Gilman, A. G., Goodman and Gilman's: (2001). The pharmacological basis of therapeutics. McGraw-Hill, New York.

82. Boisdron-Celle, M., Menei, P., and Benoit, J. P. (1995). Preparation and characterization of 5-fluorouracil-loaded microparticles as biodegradable anticancer drug carriers. J Pharm Pharmacol 47, 108-114.

83. Menei, P., Boisdron-Celle, M., Croue, A. Guy, G., Benoit, J. P. (1996). Effect of stereotactic implantation of biodegradable 5-fluorouracil-loaded microspheres in healthy and c6 glioma-bearing rats. Neurosurgery 39, 117-124.

84. Lemaire, L., Roullin, V. G., Franconi, F. et al. (2001). Therapeutic efficacy of 5-fluorouracil-loaded microspheres on rat glioma: A magnetic resonance imaging study. NMR Biomed 14, 360-366.

85. Fournier, E., Passirani, C., Montero-Menei, C, et al. (2003). Therapeutic effectiveness of novel 5-fluorouracil-loaded poly(methylidene malonate 2.1.2)-based microspheres on f98 glioma-bearing rats. Cancer 97, 2822-2829.

86. Fournier, E., Passirani, C., Vonarbourg, A. et al. (2003). Therapeutic efficacy study of novel 5-fu-loaded pmm 2.1.2-based microspheres on c6 glioma. Int J Pharm 268, 31-35.

87. Menei, P., Venier, M. C., Gamelin, E. et al. (1999). Local and sustained delivery of 5-fluorouracil from biodegradable microspheres for the radiosensitization of glioblastoma: A pilot study. Cancer 86, 325-330.

88. Menei, P., Capelle, L., Guyotat, J. et al. (2005). Local and sustained delivery of 5-fluorouracil from biodegradable microspheres for the radiosensitization of malignant glioma: A randomized phase II trial. Neurosurgery 56, 242-248; discussion 242-248.

89. Slichenmyer, W. J., Rowinsky, E. K., Donehower, R. C., Kaufmann, S. H. (1993). The current status of campto-thecin analogues as antitumor agents. J Natl Cancer Inst 85, 271-291.

90. Storm, P. B., Moriarity, J. L., Tyler, B. et al. (2002). Polymer delivery of camptothecin against 9l gliosarcoma: Release, distribution, and efficacy. J Neurooncol 56, 209-217.

91. Facoetti, A., Capelli, E., and Nano, R. (2001). HLA class I molecules expression: Evaluation of different immunocyto-chemical methods in malignant lesions. Anticancer Res 21, 2435-2440.

92. Ehninger, G., Schuler, U., Proksch, B., Zeller, K. P., Blanz, J. (1990). Pharmacokinetics and metabolism of mitoxantrone. A review. Clin Pharmacokinet 18, 365-380.

93. Wolff, J. E., Trilling, T., Molenkamp, G., Egeler, R. M., Jurgens, H. (1999). Chemosensitivity of glioma cells in vitro: A meta analysis. J Cancer Res Clin Oncol 125, 481-486.

94. Senkal, M., Tonn, J. C., Schonmayr, R. et al. (1997). Mitoxantrone-induced DNA strand breaks in cell-cultures of malignant human astrocytoma and glioblastoma tumors. J Neurooncol 32, 203-208.

95. DiMeco, F., Li, K. W., Tyler, B. M. et al. (2002). Local delivery of mitoxantrone for the treatment of malignant brain tumors in rats. J Neurosurg 97, 1173-1178.

96. Boiardi, A., Eoli, M., Salmaggi, A. et al. (2001). Efficacy of intratumoral delivery of mitoxantrone in recurrent malignant glial tumours. J Neurooncol 54, 39-47.

97. Weingart, J. D., Sipos, E. P., and Brem, H. (1995). The role of minocycline in the treatment of intracranial 9l glioma. J Neurosurg 82, 635-640.

98. Frazier, J. L., Wang, P. P., Case, D. et al. (2003). Local delivery of minocycline and systemic bcnu have synergistic activity in the treatment of intracranial glioma. J Neurooncol 64, 203-209.

99. Sills, A. K., Jr, Williams, J. I., Tyler, B. M. et al. (1998). Squalamine inhibits angiogenesis and solid tumor growth in vivo and perturbs embryonic vasculature. Cancer Res 58, 2784-2792.

100. Bhargava, P., Marshall, J. L., Dahut, W. et al. (2001). A phase I and pharmacokinetic study of squalamine, a novel antiangio-genic agent, in patients with advanced cancers. Clin Cancer Res 7, 3912-3919.

101. Kim, Y. M., Jang, J. W., Lee, O. H. et al. (2000). Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloprotei-nase. Cancer Res 60, 5410-5413.

102. Morbidelli, L., Donnini, S., Chillemi, F. Giachetti, A., Ziche, M. (2003). Angiosuppressive and angiostimulatory effects exerted by synthetic partial sequences of endostatin. Clin Cancer Res 9, 5358-5369.

103. Chillemi, F., Francescato, P., Ragg, E. et al. (2003). Studies on the structure-activity relationship of endostatin: Synthesis of human endostatin peptides exhibiting potent antiangiogenic activities. J Med Chem 46, 4165-4172.

104. Cattaneo, M. G., Pola, S., Francescato, P. Chillemi, F., Vicentini, L. M. (2003). Human endostatin-derived synthetic peptides possess potent antiangiogenic properties in vitro and in vivo. Exp Cell Res 283, 230-236.

105. Peroulis, I., Jonas, N., and Saleh, M. (2002). Antiangiogenic activity of endostatin inhibits c6 glioma growth. Int J Cancer 97, 839-845.

106. Thompson, R. C., Pardoll, D. M., Jaffee, E. M. et al. (1996). Systemic and local paracrine cytokine therapies using transduced tumour cells are synergistic in treating intra-cranial tumors. J Immunother Emphasis Tumor Immunol 19, 405-413.

107. DiMeco, F., Rhines, L. D., Hanes, J. et al. (2000). Paracrine delivery of il-12 against intracranial 9l gliosarcoma in rats. J Neurosurg 92, 419-427.

108. Sampath, P., Hanes, J., DiMeco, F. et al. (1999). Paracrine immunotherapy with interleukin-2 and local chemotherapy is synergistic in the treatment of experimental brain tumors. Cancer Res 59, 2107-2114.

109. Hanes, J., Sills, A., Zhao, Z. et al. (2001). Controlled local delivery of interleukin-2 by biodegradable polymers protects animals from experimental brain tumors and liver tumors. Pharm Res 18, 899-906.

110. Rhines, L. D., Sampath, P., DiMeco, F. et al. (2003). Local immunotherapy with interleukin-2 delivered from biodegradable polymer microspheres combined with interstitial chemotherapy: A novel treatment for experimental malignant glioma. Neurosurgery 52, 872-879; discussion 879-880.

111. Santini, J. T., Jr., Cima, M. J., and Langer, R. (1999). A controlled-release microchip. Nature 397, 335-338.

112. Santini, J. T., Jr., Richards, A. C., Scheidt, R. A. et al. (2000). Microchip technology in drug delivery. Ann Med 32, 377-379.

113. Richards Grayson, A. C., Choi, I. S., Tyler, B. M. et al. (2003). Multi-pulse drug delivery from a resorbable polymeric microchip device. Nat Mater 2, 767-772.

114. Zanta, M. A., Boussif, O., Adib, A. Behr, J. P. (1997). In vitro gene delivery to hepatocytes with galactosylated polyethyl-enimine. Bioconjug Chem 8, 839-844.

115. Boussif, O., Lezoualc'h, F., Zanta, M. A. et al. (1995). A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: Polyethylenimine. Proc Natl Acad Sci U S A 92, 7297-7301.

116. Demeneix, B., Behr, J., Boussif, O. et al. (1998). Gene transfer with lipospermines and polyethylenimines. Adv Drug Deliv Rev 30, 85-95.

117. Suh, J., Wirtz, D., and Hanes, J. (2003). Efficient active transport of gene nanocarriers to the cell nucleus. Proc Natl Acad Sci U S A 100, 3878-3882.

118. Abbott, N. J., and Romero, I. A. (1996). Transporting therapeutics across the blood-brain barrier. Mol Med Today 2, 106-113.

119. Wang, P. P., Frazier, J., and Brem, H. (2002). Local drug delivery to the brain. Adv Drug Deliv Rev 54, 987-1013.

120. Brem, H., Mahaley M. S., Jr., Vick, N. A. et al. (1991). Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. J Neurosurg 74, 441-446.

121. Brem, H., Piantadosi, S., Burger, P. C. et al. (1995). Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The polymer-brain tumor treatment group. Lance 345, 1008-1012.

122. Brem, H., Ewend, M. G., Piantadosi, S. et al. (1995). The safety of interstitial chemotherapy with bcnu-loaded polymer followed by radiation therapy in the treatment of newly diagnosed malignant gliomas: Phase I Trial. J Neurooncol 26, 111-123.

123. Valtonen, S., Timonen, U., Toivanen, P. et al. (1997). Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: A randomized double-blind study. Neurosurgery 41, 44-48.

124. Westphal, M., Hilt, D. C., Bortey, E. et al. (2003). A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (gliadel wafers) in patients with primary malignant glioma. Journal of Neuro-Oncology 5, 79-88.

125. Rosenblum, M., Weingart, J., Dolan, M. E. et al. (2002). Phase I study of gliadel combined with a continuous intravenous infusion of o6-benzylguanine in patients with recurrent malignant glioma. Proc American Soc Clin Oncologists 21.

126. Limentani, S., Asher, A., Fraser, R. et al. (1999). A phase I trial of surgery, gliadel, and carboplatin in combination with radiation therapy for anaplastic astrocytoma or glioblastoma multiforme. ASCO Annual Meeting Abstract in CD.

127. Limentani, S., Asher, A., and Fraser, R. (2000). A phase I trial of surgery, gliadel, and carboplatin in combination with radiation therapy for anaplastic astrocytoma or glioblastoma multiforme. American Association of Neurological Surgeons. Abstract in CD.

128. Colvin, O. M., Cogkor, I., Edwards, S. et al. (2000). Phase I trials of gliadel plus CPT-11 or temodar. ASCO Annual Meeting Abstract in CD.

129. Sungarian, A., Sampath, P., Maestri, X. et al (2001). Cpt-11 used in combination with bcnu-impregnated polymer (gliadel) in the treatment of recurrent glioblastoma multiforme: A preliminary clinical study. Congress of Neurological Surgeons. Abstract in CD.

130. Rich, J., Reardon, D. A., Allen, D. et al. (2001). Phase I/II trial of gliadel plus temodar for adult patients with recurrent high-grade glioma. ASCO Annual Meeting.

131. Gururangan, S., Cokgor, L., Rich, J. et al. (2001). Phase I study of gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade glioma. J Neurooncol 3, 246-250.

132. Albright, R., Breneman, J., Warnick, R. et al. (2000). A phase I study of treatment for patients with relapsed malignant glioma using concurrent permanent I-125 seeds and dose escalation of gliadel bcu polymers. American Association of Neurological Surgeons. Abstract in CD.

133. Darakchiev, B., Albright, R., Breneman, J. et al. (2004). Prolonged survival in patients with recurrent glioblastoma multiforme treaed by resection with implantation of permannent I-125 seeds and bcnu -impregnated wafers. American Association of Neurological Surgeons. Abstract in CD.

134. McPherson, C., Breneman, J., Tobler, W. et al. (2004). Permanent low activity i-125 interstitial implants as an adjuvant therapy for the treatment of newly diagnosed glioblastoma multiforme. American Association of Neurological Surgeons. Abstract in CD.

135. Lowenthal, B., Sanan, A., Shannon, M. et al. (2003). A preliminary report on patients with cns metastatic disease enrolled in prolong outcomes study. American Association of Neurological Surgeons. Abstract in CD.

136. Brem, S., Snodgrass, S., Staller, A. et al. (2003). Implantation of bcnu chemotherapreutic wafers to prevent recurrence of brain metastases. American Association of Neurological Surgeons. Abstract in CD.

137. Laws, Jr. E. R., Morris, A. M., and Maartens, N. (2003). Gliadel for pituitary adenomas and craniopharyngiomas. Neurosurgery 53, 255-269.

138. Menei, P., Jadaud, E., Faisant, N. et al. (2004). Stereotaxic implantation of 5-fluorouracil-releasing microspheres in malignant glioma. Cancer Jan 15, 100, 405-410.

139. Kleinberg, L. R., Weingart, J., Burger, P. et al. (2004). Clinical course and pathologic findings after gliadel and radiotherapy for newly diagnosed malignant glioma: Implications for patient management. Cancer Invest 22, 1-9.

140. Olivi, A., Grossman S. A., Tatter, S. et al. (2003). Dose escalation of carmustine in surgically implanted polymers in patients with recurrent malignant glioma: A new approaches to brain tumour therapy cns consortium trial. J Clin Oncol 21, 1845-1849.

141. Storm, P. B., Moriarity, J. L., Tyler, B. et al. (2002). Polymer delivery of camptothecin against 9l gliosarcoma: Release, distribution, and efficacy. J Neurooncol 56, 209-217.

142. Haque, R. (2004). Antagonism of brain-mediated excitotoxic destruction and invasion using a glutamate release inhibitor. AANS.

143. Amundson, E. (2003). SJG-136: A novel agent for the treatment of experimental gliomas: An in-vivo toxicity and efficacy study. Congress of Neurological surgeons. Abstract in CD.

144. Tyler, B. (2002). Tetra-o-methyl-nordihydroguaiaretic acid (m4m): A novel agent for the interstitial treatment of experimental brain tumors - an in vitro and in vivo assessment. Congress of Neurological surgeons. Abstract in CD.

145. Hanes, J., Sills, A., Zhao, Z. et al. (2001). Controlled local delivery of interleukin-2 by biodegradable polymers protects animals from experimental brain tumors and liver tumors. Pharm Res 18, 899-906.

146. DiMeco, F. (2001). Interleukin-12 delivery by biodegradable microspheres (IL-12 ms) for the treatment of metastatic brain tumors. AANS.

147. DiMeco, F. (2000). Local delivery of interleukin-12 by biodegradable microspheres (IL-12ms) for the treatment of experimental brain tumors. 4th Congress of the European Association of Neuro-Oncology.

148. Pradilla, G., Legnani, F., Hsu, W. Tyler, B., Brem, H. (2004). The protease inhibitor lactacystin prolongs survival in animals intracranially challenged with 9l glioksarcoma when delivered locally via controlled-release polymers. Congress of Neurological surgeons. Abstract in CD.

149. Hsu, W., Pradilla, G., Legnani, F., Tyler, B., Brem, H. (2004). Local edlivery of lactacystin via controlled-release polymers prolongs survival in a 9l gliosarcoma model. AANS.

150. Frazier, J. L., Wang, P. P., Case, D. et al. (2003). Local delivery of minocycline and systemic bcnu have synergistic activity in the treatment of intracranial glioma. J Neurooncol 64, 203-209.

151. Haroun, R., Tyler, B., and Brem, H. (2000). Chemically modified tetracyclines inhibit solid tumour growth in brain tumor models in vivo. Congress of Neurological surgeons. Abstract in CD.

152. DiMeco, F., Li, K. W., Tyler, B. M. et al. (2002). Local delivery of mitoxantrone for the treatment of malignant brain tumors in rats. J Neurosurg 97, 1173-1178.

153. Li, K. W., Dang, W., Tyler, B. M. et al. (2003). Polilactofate microspheres for paclitaxel delivery to central nervous system malignancies. Clin Cancer Res 9, 3441-3447.

154. Brem, S., Tyler, B., Legnani, F. et al. (2004). Local delivery of temozolomide against an experimental malignant glioma model. Congress of Neurological surgeons. Abstract in CD.

Brain With Brain Cancer Tumor
PLATE 19.1 (Fig. 19.1)
Malignant Glioma Market
PLATE 19.4 (Fig. 19.4)
How To Bolster Your Immune System

How To Bolster Your Immune System

All Natural Immune Boosters Proven To Fight Infection, Disease And More. Discover A Natural, Safe Effective Way To Boost Your Immune System Using Ingredients From Your Kitchen Cupboard. The only common sense, no holds barred guide to hit the market today no gimmicks, no pills, just old fashioned common sense remedies to cure colds, influenza, viral infections and more.

Get My Free Audio Book


Post a comment